# Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain

> **NCT00410943** · PHASE3 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 169 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** OROS Hydromorphone HCI SR (slow release)

## Key facts

- **NCT ID:** NCT00410943
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1999-06
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2010-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410943, "Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00410943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*